Rhythm Biosciences Limited (ASX: RHY) - Share Price
- Current share price for RHY : $0.065
Rhythm Biosciences Limited (RHY) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives.
RHY General Information +
| ASX Code | RHY |
| Website | http://www.rhythmbio.com |
| Industry/Sector | Health Care Services |
| Market Cap ($M) | 23 |
| RHY Share Price | $0.065 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.065 |
| RHY Share Price Movement | - ( No change ) |
Prices as at 16:40, 27 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Rhythm Biosciences Limited (RHY) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Rhythm Biosciences Limited (RHY) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Rhythm Biosciences Limited (RHY) price-sensitive announcements
RHY - Quarterly Activities Report and Appendix 4C
Rhythm Biosciences’ Quarterly Activities Report and Appendix 4C for the Australian first q
Rhythm Biosciences Limited (RHY)
27 Oct 2026 | 8:22 AM
27 Oct 2026 | 8:22 AM
RHY - ColoSTAT Economic Study - Australian Public Health Savings
Rhythm Biosciences announced the results of an independent health economic study by Value-
Rhythm Biosciences Limited (RHY)
7 Oct 2026 | 9:10 AM
7 Oct 2026 | 9:10 AM
RHY - Initial ColoSTAT Assessment in UK opens new market access
Rhythm Biosciences announced that the Southern Hub research laboratory at the Royal Surrey
Rhythm Biosciences Limited (RHY)
22 Sep 2026 | 8:24 AM
22 Sep 2026 | 8:24 AM
RHY - FY26 Appendix 4E & Audited Financial Report
Rhythm Biosciences Limited’s FY26 Appendix 4E and audited financial report for the Austral
Rhythm Biosciences Limited (RHY)
27 Aug 2026 | 5:04 PM
27 Aug 2026 | 5:04 PM
Rhythm Biosciences Limited (RHY) Recent ASX Announcements
RHY Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$5.93 | -$1.80 | 30.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$3.66 | -$1.40 | -54.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$6.86 | -$3.00 | -19.10% | 0.00 | 0.00 | 0.00% | 0.0% |
RHY Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Australian Clinical Labs Limited (ACL) | $556M | 0.0442 | -0.0111 | 0.0428 | 15.7589 | 15.9358 | 15.2821 | 4.36% | 4.36% | 4.19% |
| Integral Diagnostics Limited (IDX) | $781M | 0.7037 | 0.0000 | 0.1877 | 16.0153 | 16.0153 | 13.4839 | 4.45% | 3.59% | 4.07% |
| Rhythm Biosciences Limited (RHY) | $23M | 0.3015 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Sonic Healthcare Limited (SHL) | $9,435M | 0.2969 | -0.1774 | 0.1040 | 13.7953 | 16.7706 | 15.1906 | 5.66% | 5.50% | 5.79% |
RHY Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 6.50 | 0.00 |
| Market | 0.30 | 13.30 | 1.03 | 0.72 |
| Sector | 0.74 | 22.00 | 1.82 | 2.48 |
RHY Directors
| Name | Position | Start Date |
|---|---|---|
| Dr David Atkins | Chief Executive Officer, Managing Director | 30 Sep 2024 |
| Mr Carl Stubbings | Non-Executive Director | 27 Aug 2026 |
| Ms Maureen Lee Baker | Non-Executive Director | 27 Aug 2026 |
| Ms Sue(Susan) MacLeman | Non-Executive Director, Interim Chairman | 31 Jan 2023 |
Rhythm Biosciences Limited (RHY) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 1 Dec 2025 | ATKINS, David | Issued | Indirect Shares | 1,093,001 | $0.099 | $108,300.100 |
| 1 Dec 2025 | MACLEMAN, Sue(Susan) | Issued | Indirect Shares | 450,000 | $0.100 | $45,000.000 |
| 1 Dec 2025 | FOX-SMITH, Gavin | Issued | Indirect Shares | 1,027,777 | $0.097 | $99,999.930 |
See all changes in directors' interest & trades for Rhythm Biosciences Limited (RHY) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
RHY Management
| Name | Position |
|---|---|
| Andrea Steele | Company Secretary,General Counsel |
| James Stephen Barrie | Joint Company Secretary |
RHY Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Rhythm Biosciences Limited (RHY). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 36,384,575 (11.29%) | Otto Buttula |
| 24,811,804 (8.53%) | FIL Limited and the entities |
RHY Calendar of Events
| Date | Event |
|---|---|
| 28 September 2027 | Report (Annual) |
| 26 August 2027 | Report (Annual) |
| 26 August 2027 | Report (Prelim) |
| 17 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
